Adrian Sacher

Assistant Professor

University of Toronto

Canada

Research Interests

Explore related searches

Professors in Canada Professors in Immunology Immunology professors in Canada

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Adrian Sacher is an Assistant Professor at the University of Toronto, Canada. His research focuses on lung cancer, particularly the molecular determinants of treatment efficacy, the impact of tyrosine kinase inhibitors, and clinical outcomes in non-small cell lung cancer. Recent publications include studies on the common pathophysiology of lung cancer and cardiovascular disease, as well as real-world assessments of treatment effectiveness in patients with advanced lung cancer.

Articles (20)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Collaborators (5)

Ming Sound Tsao

University Health Network

CANADA

View details

Louis Pinard

Staff Nephrologist, Clinical Assistant Professor

Centre Hospitalier de l'Université de Montréal Centre de Recherche

CANADA

View details

Nicolas Jacquelot

University of Calgary

CANADA

View details

Vijithan Sugumar

University of Toronto Faculty of Medicine

CANADA

View details

Alessandra Curioni-Fontecedro

Professor of Oncology

University of Fribourg

SWITZERLAND

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Adrian Sacher

Research Interests

Explore related searches

Contact this professor

About

Articles (20)

Lung Cancer and Cardiovascular Disease: Common Pathophysiology and Treatment-Emergent Toxicity.

Molecular determinants of sotorasib clinical efficacy in KRAS<sup>G12C</sup>-mutated non-small-cell lung cancer.

Savolitinib plus osimertinib in epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer with MET overexpression and/or amplification following disease progression on osimertinib: primary results from the phase II SAVANNAH study.

Early phase trials: the perils of nonpublication.

Real-World Creatinine-Based Estimates of Acute and Chronic Kidney Dysfunction in Patients with Advanced ALK-Rearranged Non-Small-Cell Lung Cancer Receiving Tyrosine Kinase Inhibitors.

Retrospective cohort study assessing clinical outcomes of patients with extensive-stage small cell lung cancer treated with and without consolidative thoracic radiotherapy at the Princess Margaret Cancer Centre.

Health Utility and Symptom Scores in Patients With Advanced Malignant Pleural Mesothelioma Treated in a Real-World Setting.

Prognostic and predictive effects of TP53 co-mutation in patients with non-small cell lung cancer with rare treatable driver mutations.

Assessing the feasibility and external validity of natural language processing-extracted data for advanced lung cancer patients.

Real-world outcomes of prophylactic cranial irradiation utilization and efficacy for patients with extensive-stage small cell lung cancer treated with consolidative thoracic radiotherapy.

Predictive radiomics signature for treatment response to nivolumab in patients with advanced renal cell carcinoma

Clinicopathologic factors that influence prognosis and survival outcomes in men with metastatic castration-resistant prostate cancer treated with Radium-223

Durability of CNS disease control in NSCLC patients with brain metastases treated with immune checkpoint inhibitors plus cranial radiotherapy

Durvalumab therapy following chemoradiation compared with a historical cohort treated with chemoradiation alone in patients with stage III non–small cell lung cancer: A real-world multicentre study

Natural killer cells and type 1 innate lymphoid cells in hepatocellular carcinoma: Current knowledge and future perspectives

Prevalence and Heterogeneity of PD-L1 Expression by 22C3 Assay in Routine Population-Based and Reflexive Clinical Testing in Lung Cancer

Sotorasib for lung cancers with KRAS P.G12C mutation

Subtypes of EGFR- and HER2-Mutant Metastatic NSCLC Influence Response to Immune Checkpoint Inhibitors

Systemic Inflammatory Markers of Survival in Epidermal Growth Factor–Mutated Non–Small-Cell Lung Cancer: Single-Institution Analysis, Systematic Review, and Meta-analysis

The impact of symptoms and comorbidity on health utility scores and health-related quality of life in small cell lung cancer using real world data

Collaborators (5)

Ming Sound Tsao

Louis Pinard

Nicolas Jacquelot

Vijithan Sugumar

Alessandra Curioni-Fontecedro

Make your next move.

Adrian Sacher

Research Interests

Explore related searches

Contact this professor

About

Articles (20)

Lung Cancer and Cardiovascular Disease: Common Pathophysiology and Treatment-Emergent Toxicity.

Molecular determinants of sotorasib clinical efficacy in KRAS&lt;sup&gt;G12C&lt;/sup&gt;-mutated non-small-cell lung cancer.

Savolitinib plus osimertinib in epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer with MET overexpression and/or amplification following disease progression on osimertinib: primary results from the phase II SAVANNAH study.

Early phase trials: the perils of nonpublication.

Real-World Creatinine-Based Estimates of Acute and Chronic Kidney Dysfunction in Patients with Advanced ALK-Rearranged Non-Small-Cell Lung Cancer Receiving Tyrosine Kinase Inhibitors.

Retrospective cohort study assessing clinical outcomes of patients with extensive-stage small cell lung cancer treated with and without consolidative thoracic radiotherapy at the Princess Margaret Cancer Centre.

Health Utility and Symptom Scores in Patients With Advanced Malignant Pleural Mesothelioma Treated in a Real-World Setting.

Prognostic and predictive effects of TP53 co-mutation in patients with non-small cell lung cancer with rare treatable driver mutations.

Assessing the feasibility and external validity of natural language processing-extracted data for advanced lung cancer patients.

Real-world outcomes of prophylactic cranial irradiation utilization and efficacy for patients with extensive-stage small cell lung cancer treated with consolidative thoracic radiotherapy.

Predictive radiomics signature for treatment response to nivolumab in patients with advanced renal cell carcinoma

Clinicopathologic factors that influence prognosis and survival outcomes in men with metastatic castration-resistant prostate cancer treated with Radium-223

Durability of CNS disease control in NSCLC patients with brain metastases treated with immune checkpoint inhibitors plus cranial radiotherapy

Durvalumab therapy following chemoradiation compared with a historical cohort treated with chemoradiation alone in patients with stage III non–small cell lung cancer: A real-world multicentre study

Natural killer cells and type 1 innate lymphoid cells in hepatocellular carcinoma: Current knowledge and future perspectives

Prevalence and Heterogeneity of PD-L1 Expression by 22C3 Assay in Routine Population-Based and Reflexive Clinical Testing in Lung Cancer

Sotorasib for lung cancers with KRAS P.G12C mutation

Subtypes of EGFR- and HER2-Mutant Metastatic NSCLC Influence Response to Immune Checkpoint Inhibitors

Systemic Inflammatory Markers of Survival in Epidermal Growth Factor–Mutated Non–Small-Cell Lung Cancer: Single-Institution Analysis, Systematic Review, and Meta-analysis

The impact of symptoms and comorbidity on health utility scores and health-related quality of life in small cell lung cancer using real world data

Collaborators (5)

Ming Sound Tsao

Louis Pinard

Nicolas Jacquelot

Vijithan Sugumar

Alessandra Curioni-Fontecedro

Make your next move.

Molecular determinants of sotorasib clinical efficacy in KRAS<sup>G12C</sup>-mutated non-small-cell lung cancer.